Ranbaxy In Bear Grip As Sales Slip In U.S. After FDA Restrictions

MUMBAI - India's Ranbaxy, now part of Japanese drug maker Daiichi Sankyo, has witnessed a sharp drop in its market share in the U.S., having lost as much as 40 percent in sales since last August. The drop in prescriptions is at a staggering 50 percent as compared to the company's February 2008 sales data. According to a Deutsche Bank report, this indicates that Ranbaxy will lose further prescriptions and hence revenues